Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
Huang X, Qiu L, Jin J, Zhou D, Chen X, Hou M, Hu J, Hu Y, Ke X, Li J, Liang Y, Liu T, Lv Y, Ren H, Sun A, Wang J, Zhao C, Salman M, Sun S, Howes A, Wang J, Wu P, Li J.
Huang X, et al. Among authors: hu j, hu y.
Cancer Med. 2018 Apr;7(4):1043-1055. doi: 10.1002/cam4.1337. Epub 2018 Mar 13.
Cancer Med. 2018.
PMID: 29533000
Free PMC article.
Clinical Trial.